Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-11-07
2006-11-07
Hayes, Robert C. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
07132396
ABSTRACT:
The present invention relates to novel compounds and their uses, in particular their pharmaceutical or diagnostic uses or their use as pharmacological targets. More particularly, the present invention relates to a novel protein, referred to as PAP1, as well as to novel peptides and compounds which are capable of modulating, at least partially, the activity of parkin.
REFERENCES:
patent: WO 01/46256 (2000-12-01), None
Pudingen, In “Peptide Hormones” (ed. J.A. Parsons) University Park Press, Baltimore, pp. 1-7, 1976.
Stratagene Product Catalog. Product #300071 La Jolla, CA, p. 95, 1991.
Kitada, T., et al; Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism; Nature, vol. 329, Apr. 9, 1998, 605-608.
Abbas, N., et al.; A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe; Hum. Mol. Genet., vol. 8, 1999, 567-574.
Hattori, N., et al.; Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism; Ann Neurol., vol. 6, 1998, 935-941.
Lucking, C., et al.; Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism; Lancet, vol. 352, 1998, 1355-1356.
Morett, E. et al.; A novel transactivation domain in parkin; Trends Biochem Sci., vol. 24, 1999, 229-231.
Polymeropoulos, M.H., et al.; Mutation in the alpha-synuclein gene identified in families with Parkinson's disease; Science, vol. 276, 1997, 2045-2047.
Shimura, H., et al.; Immunohistochemical and subcellular locallzation of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients; Ann Neurol., vol. 45, 1999, 668-672.
Sunada, Y., et al.; Differential expression of the parkin gene in the human brain and peripheral leukocytes; Neurosci Lett., vol. 254, 1998, 180-182.
Mellick, G.D. et al.; The parkin gene S/N167 polymorphism in Australian Parkinson's disease patients and controls; Parkinsonism and Related Disorders 7, 2001, 89-91.
Arnould-Reguigne Isabelle
Brice Alexis
Corti Olga
Fournier Alain
Koutnikova Hana
Aventis Pharma S.A.
Hayes Robert C.
Wiley Rein & Fielding LLP
LandOfFree
Compositions which can be used for regulating the activity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions which can be used for regulating the activity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions which can be used for regulating the activity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3698487